OBIO.US Orchestra BioMed Holdings Inc.

Healthcare Biotechnology USA Stocks
7.12 USD
Close of Nov 16, 2026
3.46 7.45
Market cap
USD 560M
P/E
-
P/B
73.02x
ROE
-449.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OBIO.US undervalued?

Graham number

The Graham number of Orchestra BioMed Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orchestra BioMed Holdings Inc. fundamental analysis

No fundamental analysis for Orchestra BioMed Holdings Inc. yet.

Orchestra BioMed Holdings Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of c…

Full company profile